This clinical study highlights the disease-relevance of changes in systemic levels of inflammatory cytokines, including IL-1β, IL-6, IL-12, GM-CSF, TGF-β1, and IFN-γ as well as the therapeutic efficacy of PG2 as a cancer symptom cluster-alleviating, QoL-improving, inflammation-limiting, adjunct therapy for patients with metastatic or advanced stage cancer. Here, CSF2 is linked to cancer.